




Searching News Database: Single-Site
HSMN NewsFeed - 21 Nov 2024
SOPHiA GENETICS Launches MSK-IMPACT(R) powered with SOPHiA DDM(TM) at AMP 2024
SOPHiA GENETICS Launches MSK-IMPACT(R) powered with SOPHiA DDM(TM) at AMP 2024
HSMN NewsFeed - 26 Feb 2024
Study Using IceCure's ProSense(R) Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer
Study Using IceCure's ProSense(R) Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer
HSMN NewsFeed - 10 Nov 2023
EU Approval of AAV5 DetectCDx(TM) Provides Access to Companion Diagnostic for Hemophilia A Gene Therapy
EU Approval of AAV5 DetectCDx(TM) Provides Access to Companion Diagnostic for Hemophilia A Gene Therapy
HSMN NewsFeed - 23 Jul 2015
Medrobotics(R) Corporation Receives FDA Clearance to Market Flex(R) Robotic System
Medrobotics(R) Corporation Receives FDA Clearance to Market Flex(R) Robotic System
HSMN NewsFeed - 19 Jun 2012
Titan Medical Inc. Announces Early-User Study Testing Results for Robotic Single-Site Surgical Platform
Titan Medical Inc. Announces Early-User Study Testing Results for Robotic Single-Site Surgical Platform
HSMN NewsFeed - 7 Jun 2012
Titan Medical Inc. Announces Addition of Dr. Dennis L. Fowler, MD, MPH as Development Consultant
Titan Medical Inc. Announces Addition of Dr. Dennis L. Fowler, MD, MPH as Development Consultant
HSMN NewsFeed - 12 Oct 2010
Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs
Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs
HSMN NewsFeed - 30 Apr 2009
Cardica Develops the Cardica Microcutter, The First True Multi-Fire Endolinear Cutter
Cardica Develops the Cardica Microcutter, The First True Multi-Fire Endolinear Cutter
HSMN NewsFeed - 18 Sep 2007
New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
HSMN NewsFeed - 2 May 2007
Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease
Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease
HSMN NewsFeed - 22 Dec 2006
Synthetic Blood Reports Positive Preliminary Results From Traumatic Brain Injury Clinical Trial
Synthetic Blood Reports Positive Preliminary Results From Traumatic Brain Injury Clinical Trial
Additional items found! 5

Members Archive contains
5 additional stories matching:
Single-Site
(Password required)
Single-Site
(Password required)